Most Read Articles
2 days ago
Tetanus toxoid 5 Lf, diphtheria toxoid 2 Lf, pertussis toxoid 2.5 mcg, filamentous haemagglutinin 5 mcg, fimbriae types 2 and 3 5 mcg, pertactin 3 mcg
Pearl Toh, 22 Oct 2020
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Jairia Dela Cruz, Yesterday
The selective serotonin reuptake inhibitor escitalopram holds promise in the prevention of Alzheimer’s disease, reducing amyloid-β-42 levels in cerebrospinal fluid and brain tissue in older adults with normal cognitive function, according to recent evidence.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

Visual axis opacity common after IOL implantation in children

16 Sep 2020
Abbott opens us$60 million plant in Kedah

Visual axis opacity (VAO) frequently occurs following intraocular lens (IOL) implantation in early childhood, a recent study has found.

This population-based (UK and Ireland) prospective, inception cohort study was conducted through a national clinical network, including 105 children (n=162 eyes; 57 with bilateral cataract, 48 with unilateral cataract) undergoing primary IOL implantation in the first 2 years of life between January 2009 and December 2010.

The authors also performed an observational longitudinal study with multilevel, multivariable modeling to assess the associations between outcome of interest and child- and treatment-specific factors, including age, axial length, socioeconomic status, IOL model, and postoperative steroid use.

Sixty-seven eyes (45 percent) developed VAO typically within the first postoperative year. Use of a 3-pice IOL model (odds ratio [OR], 0.3, 95 percent confidence interval [CI], 0.09–0.99; p=0.03) and increasing age at surgery (OR, 0.97, 95 percent CI, 0.95–0.99; p=0.02) each showed a protective effect against the development of proliferative VAO.

Moreover, inflammatory VAO independently correlated with socioeconomic deprivation (OR, 5.39, 95 percent CI, 1.46–19.89; p=0.01).

“The findings of this prospective cohort study suggest that the use of 3-piece IOL models may reduce the risk of pseudophakic VAO in children younger than 2 years of age,” the authors said.

“Appropriate correction of aphakia is key to good outcomes. Strategies to target the increased risk of VAO after primary IOL implantation in infancy are necessary,” they added.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
2 days ago
Tetanus toxoid 5 Lf, diphtheria toxoid 2 Lf, pertussis toxoid 2.5 mcg, filamentous haemagglutinin 5 mcg, fimbriae types 2 and 3 5 mcg, pertactin 3 mcg
Pearl Toh, 22 Oct 2020
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Jairia Dela Cruz, Yesterday
The selective serotonin reuptake inhibitor escitalopram holds promise in the prevention of Alzheimer’s disease, reducing amyloid-β-42 levels in cerebrospinal fluid and brain tissue in older adults with normal cognitive function, according to recent evidence.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.